News tagged with epidermal growth factor receptor
Related topics: patients , breast cancer , cancer , lung cancer , cancer cells
Vandetanib doesn't up survival in non-small-cell lung cancer
(HealthDay) -- Vandetanib does not improve overall survival for patients who have received previous treatment for advanced non-small-cell lung cancer (NSCLC), according to a study published online Feb. 27 ...
Cancer
Mar 02, 2012 |
not rated yet |
0
Discovery predicts patient sensitivity to important drug target in deadly brain cancer
A recent discovery by Van Andel Research Institute (VARI) scientists enables the prediction of patient sensitivity to proposed drug therapies for glioblastoma – the most common and most aggressive malignant brain tumor ...
Cancer
Feb 06, 2012 |
4 / 5 (2) |
0
|
The link between TB and a gene mutation that causes lung cancer
Tuberculosis (TB) has been suspected to increase a person's risk of lung cancer because the pulmonary inflammation and fibrosis can induce genetic damage. However, direct evidence of specific genetic changes and the disease ...
Cancer
Jan 18, 2012 |
not rated yet |
0
Studies help clarify the role of lapatinib and trastuzumab in treating HER2 positive breast cancer
In patients with HER2-positive breast cancer, Tykerb (lapatinib) has been used both in combination with herceptin (trastuzumab) and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy treatment. ...
Cancer
Jan 16, 2012 |
5 / 5 (2) |
0
|
Proteins do not predict outcome of herceptin treatment in HER2-positive breast cancer
Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer ...
Cancer
Dec 09, 2011 |
not rated yet |
0
Obese patients with HER2-positive breast cancer may have worse outcomes
Obese patients with early-stage HER2-positive breast cancer may have worse outcomes than patients who are normal weight or overweight, Mayo Clinic researchers found in a study presented today at the 2011 CTRC-AACR San Antonio Breast Ca ...
Cancer
Dec 08, 2011 |
not rated yet |
0
New approaches may prevent certain side effects in BRAF mutation-positive melanoma
Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, ...
Cancer
Nov 13, 2011 |
not rated yet |
0
EGFR essential for the development of pancreatic cancer
The epidermal growth factor receptor (EGFR) gene is essential for KRAS-driven pancreatic cancer development, according to study results presented at the Second AACR International Conference on Frontiers in Basic Cancer Research, ...
Cancer
Sep 15, 2011 |
5 / 5 (1) |
0
Targeting cholesterol to fight deadly brain cancers
Blocking the uptake of large amounts of cholesterol into brain cancer cells could provide a new strategy to battle glioblastoma, one of the most deadly malignancies, researchers at UCLA's Jonsson Comprehensive Cancer Center ...
Cancer
Sep 15, 2011 |
not rated yet |
0
|
Study points to strategy for overcoming resistance to targeted cancer drug
Scientists at Dana-Farber Cancer Institute and colleagues overseas have discovered a pair of backup circuits in cancer cells that enable the cells to dodge the effect of a widely used cancer drug. Jamming those circuits with ...
Cancer
Sep 07, 2011 |
5 / 5 (2) |
0
|
EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to research presented at the ...
Cancer
Jul 05, 2011 |
not rated yet |
0
High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy
High epidermal growth factor receptor (EGFR) expression was a good predictor of which lung cancer patients would survive longer when cetuximab (Erbitux) was added to first-line chemotherapy, according to research presented ...
Cancer
Jul 05, 2011 |
not rated yet |
0
PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumors
A non-invasive PET imaging technique may identify lung cancers that respond best to tyrosine kinase inhibitors (TKIs), allowing doctors to better select patients for personalized therapy, according to research presented at ...
Cancer
Jul 05, 2011 |
not rated yet |
0
A drug combination extends survival in refractory lung cancer patients
Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies. They found that bexarotene and erlotinib can each ...
Cancer
Jun 02, 2011 |
not rated yet |
0
Less toxic combination of erlotinib and bevacizumab is effective non-small cell lung cancer patients
The standard treatment for patients with advanced non-small cell lung cancer (NSCLC) is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity. Now, Fox ...
Cancer
Jun 01, 2011 |
not rated yet |
0
